Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.38 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.38 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13772762 | 0.96 | ESR1 (0.42) | HTR7NR1I2SLC6A3SLC6A2DRD2 | |
| SCHEMBL18885441 | 0.94 | NR1I2 (0.49) | HTR7NR1I2 | |
| SCHEMBL19231987 | 0.94 | NR1I2 (0.47) | HTR7NR1I2SLC6A3SLC6A2DRD2 | |
| SCHEMBL20633856 | 0.92 | NR1I2 (0.50) | HTR7NR1I2 | |
| SCHEMBL21346544 | 0.92 | NR1I2 (0.50) | HTR7NR1I2 | |
| SCHEMBL24445184 | 0.92 | NR1I2 (0.50) | HTR7NR1I2SLC6A3SLC6A2DRD2 | |
| SCHEMBL8221576 | 0.90 | NR1I2 (0.45) | HTR7NR1I2 | |
| SCHEMBL11852885 | 0.88 | HTR7 (0.41) | HTR7NR1I2GABBR2GABBR1 | |
| SCHEMBL27733589 | 0.88 | NR1I2 (0.37) | HTR7NR1I2SLC6A3SLC6A2DRD2 | |
| SCHEMBL13086684 | 0.86 | ESR1 (0.47) | SLC6A3SLC6A2GABBR2GABBR1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10472372-B2 | HIV-1 protease inhibitors and uses thereof | PURDUE RESEARCH FOUNDATION (US) | 2019-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10472372-B2 | HIV-1 protease inhibitors and uses thereof | SERPINB1, FURIN, PRSS1 | HTR7 3301/4885NR1I2 1909/4885SLC6A3 4815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.